Physician profile
Anas Alsara
NPI 1932498599
$3,155.74
in general payments reported to CMS, 2019-2025
40 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2021: $11.07 · 2022: $25.62 · 2023: $876 · 2024: $664 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,497.74 |
| Education | $101.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $582.34 | 2023-2025 | |
| Genentech USA, INC. | $372.26 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $209.37 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Pfizer INC. | $173.48 | 2023-2025 | |
| Incyte Corporation | $120.57 | 2019-2025 | Monjuvi |
| Merck Sharp & Dohme LLC | $101.49 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Aveo Pharmaceuticals, INC. | $99.35 | 2023-2025 | Fotivda |
| Eisai INC. | $96.39 | 2023-2025 | |
| Array Biopharma INC | $95.04 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Celgene Corporation | $86.63 | 2023-2025 | Reblozyl, Opdivo |
| Astellas Pharma US INC | $81.99 | 2023 | |
| Janssen Biotech, INC. | $79.70 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $76.14 | 2021-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $70.62 | 2025 | Fruzaqla |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $66.22 | 2023-2025 | Trodelvy |
| Sobi, INC | $56.36 | 2023-2025 | |
| Amgen INC. | $54.12 | 2023 | Xgeva, Nplate, Vectibix |
| Glaxosmithkline, LLC. | $53.69 | 2024-2025 | Ojjaara, Nucala |
| Jazz Pharmaceuticals INC. | $49.20 | 2025 | |
| Tempus Ai, INC | $44.69 | 2025 | Xt Cdx |
| Genzyme Corporation | $43.47 | 2023-2025 | |
| Springworks Therapeutics, INC. | $40.92 | 2024-2025 | Ogsiveo |
| Lilly USA, LLC | $39.89 | 2023 | Verzenio, Jaypirca, Retevmo |
| Tesaro, INC. | $35.43 | 2019 | |
| Stemline Therapeutics INC. | $33.90 | 2025 | Orserdu |
| Kite Pharma, INC. | $30.90 | 2023 | Yescarta |
| Telix Pharmaceuticals | $25.62 | 2022 | |
| Taiho Oncology, INC. | $24.43 | 2024 | |
| Genmab U.S., INC. | $23.60 | 2025 | Epkinly |
| Progenics Pharmaceuticals, INC. | $21.88 | 2024 | |
| Lundbeck LLC | $21.28 | 2025 | Vyepti |
| Tolmar, INC. | $20.68 | 2023 | |
| Sumitomo Pharma America, INC. | $20.45 | 2024 | Orgovyx |
| Emd Serono, INC. | $20.23 | 2024 | |
| Puma Biotechnology, INC. | $19.10 | 2025 | |
| Servier Pharmaceuticals LLC | $18.22 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.65 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.69 | 2024 | Ultomiris |
| Daiichi Sankyo INC. | $13.80 | 2025 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Alsara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.